Company Media
Immuron's IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81%
8 March 2018
Immuron’s shares surge on demonstrating proof of concept for liver drug candidate
8 March 2018
Results in: IMC’s lead drug reduces major factor in liver inflammation
8 March 2018
Blockbuster Results from IMC’s NASH Liver Therapy Trials
8 March 2018
Immuron reduces liver inflammation
2 March 2018
How Do You Recruit Patients Unaware Of Their Disease?
1 March 2018
Immuron's fatty liver disease candidate advancing — 4 insights
14 September 2017
In dash to NASH, Immuron targets the gut not the liver
28 March 2017
Biotech tackles hospital infection
17 March 2017